|Table of Contents|

The effect of transcatheter arterial chemoembolization on reactivation of virus in patients with hepatitis C virus-associated hepatocellular carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 06
Page:
993-997
Research Field:
Publishing date:

Info

Title:
The effect of transcatheter arterial chemoembolization on reactivation of virus in patients with hepatitis C virus-associated hepatocellular carcinoma
Author(s):
Shen Jie1; Liu Gang1; Li Sensen2; Zhang Lei1; Li Li'an1
1.Central Hospital of Luohe,Henan Luohe 462300，China;2.Department of Microbiology and Biochemistry,School of Life Science and Technology,China Pharmaceutical University,Jiangsu Nanjing 210009，China.
Keywords:
hepatitis C virus; reactivation; hepatocellular carcinoma; transcatheter arterial chemoembolization; hepatitis flare
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2019.06.022
Abstract:
Objective:To investigate the effect of transcatheter arterial chemoembolization (TACE) on hepatitis C virus reactivation and hepatitis flare in patients with hepatitis C virus-associated hepatocellular carcinoma.Methods:The clinical data of patients who diagnosed with hepatitis C virus-associated hepatocellular carcinoma between January 1,2013 and October 31,2017 were statistically analyzed.Results:156 patients with hepatitis C virus-associated hepatocellular carcinoma were enrolled in the study.A statistical study of the risk of reactivation of hepatitis C virus activity by TACE revealed that 74 patients with TACE surgery had 19 cases of hepatitis C virus reactivation,and 82 patients who did not undergo TACE had 6 cases of hepatitis C virus reactivation,and there was a statistically significant difference (P=0.00).Evaluation of the risk of reactivation of hepatitis C virus with TACE showed that HCV RNA reactivation occurred in 19 of 74 patients with TACE surgery.The preoperative WBC count in the HCV reactivated group was lower than the unactivated group,and there was a statistical difference between the two groups (P=0.02).Lg (HCV RNA) was different in the two groups,and patients with Lg (HCV RNA)≥4 had a greater probability of virus reactivation than patients with Lg (HCV RNA)<4,and there was a statistical difference between the two groups (Fisher exact test P=0.03).Tumor diameter was different between the two groups,and the probability of virus reactivation in patients with tumor diameter <6 cm was less than that of tumors ≥6 cm,and the difference was statistically significant (P=0.03).Logistic multivariate regression analysis found that WBC levels,Lg (HCV RNA) and tumor diameter before treatment were predictors of hepatitis C virus reactivation.Finally,the correlation between the incidence of hepatitis and the reactivation of hepatitis C virus showed that the probability of hepatitis in the HCV reactivation group was significantly higher than that of HCV stabilization group (P=0.01).Conclusion:The patients with hepatitis C-related hepatocellular carcinoma receiving TACE increased the risk of viral C reactivation,and WBC level,Lg (HCV RNA),tumor diameter are independent risk factors for reactivation of HCV virus,and hepatitis may be increased by HCV reactivation increased.

References:

［1］ Chen W,Zheng R,Baade PD,et al.Cancer statistics in China 2015［J］.CA Cancer J Clin,2016,66(2):115-132.
[2] Wu MC,Tang ZY,Liu YY,et al.Guidelines for diagnosis and treatment of primary liver cancer (2017 edition)［J］.Chinese Journal of Practical Surgery,2017,37(7):705-720.［吴孟超,汤钊猷,刘允怡,等.原发性肝癌诊疗规范（2017年版）［J］.中国实用外科杂志,2017,37(7):705-720.］
[3] Hsieh MY,Lin ZY,Chen SH,et al.Risk factors for the leakage of chemotherapeutic agents to systemic circulation after transcatheter arterial chemoembolization of hepatocellular carcinoma［J］.Kaohsiung J Med Sci,2011,27(10):431-436.
[4] Vento S,Cainelli F,Longhi MS.Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy:An unresolved issue［J］.Lancet Oncol,2002,3(6):333-340.
[5] Lao XM,Luo G,Ye LT,et al.Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinom［J］.Liver International,2013,33(4):595-604.
[6] Liaw YF,Kao JH,Piratvisuth T,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:A 2012 update［J］.Hepatol Int,2012,6(3):531-561.
[7]Lencioni R,Baere T,Soulen MC,et al.Lipiodol transarterial chemoembolization for hepatocellular carcinoma:A systematic review of efficacy and safety data［J］.Hepatology，2016,64(1):106-116.
[8] Torres HA,Davila M.Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer［J］.Nat Rev Clin Oncol,2012,9(3):156-166.
[9] Schlachterman A,Craft WW,Hilgenfeldt E,et al.Current and future treatments for hepatocellular carcinoma［J］.World Journal of Gastroenterology,2015,21(28):8478-8491.
[10] Lim HL,Hyun SB,Bohyun J,et al.Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy［J］.Gut and Liver,2017,11(6):870-877.
[11] Jang JW,Choi JY,Bae SH,et al.A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization［J］?Hepatology,2006,43(2):233-240.
[12]Chen GF,Li B.Progress and prospects of treatment of chronic hepatitis C virus infection［J］.Journal of Medical Research,2015,44(10):1-4.［陈国凤，李冰.慢性丙型肝炎病毒感染治疗进展及展望［J］.医学研究杂志，2015,44(10):1－4.］
[13] Huo TI,Lee SD,Wu JC.Hepatitis after arterial embolization for hepatocellular carcinoma:Viral reactivation or ischemia［J］?Hepatology,2006,43(6):1400-1401.
[14] Shang Chunyu,Su Hongying,Liu Jing,et al.Multivariate analysis of prognosis of hepatic arterial chemoembolization (TACE) in primary hepatic carcinoma［J］.Modern Oncology,2011,19(12):2466-2469.［尚春雨,苏洪英,刘静,等.原发性肝癌肝动脉化疗栓塞术（TACE）预后多因素分析［J］.现代肿瘤医学,2011,19(12):2466-2469.］

Memo

Memo:
-
Last Update: 1900-01-01